Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px
Document › Details

ImaBiotech S.A.S.. (3/29/16). "Press Release: ImaBiotech’s First Worldwide Patent Has Been Granted for Its Quantification Innovation in MSI". Lille.

Region Region United States (USA)
Organisation Organisation ImaBiotech S.A.S.
  Group ImaBiotech (Group)
Products Product Quantinetix™ software for quantitative MALDI imaging
  Product 2 mass spectrometry imaging (MSI) (MALDI imaging)
Persons Person Stauber, Jonathan (ImaBiotech 201206 CEO)
  Person 2 Fontaine, Edma (ImaBiotech 201512 Communication Manager)
     


First worldwide patent has been granted covering ImaBiotech’s research and services platform in the field of Mass Spectrometry Imaging (MSI).

ImaBiotech, a CRO company developing and offering new imaging technologies, applications and software, announces today that the company has been granted a patent in USA, France, Australia
and China for its lead innovation on quantitative MS Imaging (QMSI) and the development of the associated software, Multimaging.

Specifically, the QMSI patent covers the working method, the strategy, the method of validation, the
application, and the use of quantitative Mass Spectrometry Imaging including MALDI Imaging.

“This is a positive recognition of our hard work”, said Jonathan Stabuer, Chief Executive Officer of ImaBiotech. “The progress and recognition of our QMSI and MALDI Imaging services are now
supporting ImaBiotech’s growth and development of our US operations and facility. This patent coverage is critical for our ongoing efforts.”


About ImaBiotech

Located in Europe (France) and North America (Cambridge, MA), ImaBiotech (www.imabiotech.com) develops and offers services with new imaging technologies (Quantinetix™, Multimaging™) and applications. In order to accelerate drug development, ImaBiotech offers Mass Spectrometry Services to provide a cost-effective solution to preclinical and clinical studies. This molecular technique is used for qualitative & quantitative efficacy and toxicity of drug candidates from the whole body to cell levels.


Edma Fontaine,
ImaBiotech
Communication Manager
E: contact@imabiotech.com
T: +33 (0) 320 164 091

   
Record changed: 2016-03-30

Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px

More documents for ImaBiotech (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA September 600x60px




» top

Advertisements

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 22 Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 40